NCT02671448Active, not recruiting
Pilot Trial of Homebound Stem Cell Transplantation
Source: ClinicalTrials.gov · Last updated 14 Jul 2026
Brief summary (registry, in English)
In this study, the investigators plan to see what happens when a person receives care in the home setting. They want to find out if caring for a patient who has been treated with an ASCT in the home setting is feasible. They want to find out what effects good and/or bad this will have on the patient's recovery and treatment after ASCT. Studies in other institutions have shown that providing care in the home setting after ASCT is safe, increases patient satisfaction, and can decrease the risk of infection. It is our hope that this new approach of providing care in the home setting will prove to be a feasible and safe option for patients at Memorial Sloan Kettering Cancer Center (MSK).
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 83 (actual)
- First submitted
- 28 Jan 2016
- Start date
- Jan 2016
- Primary completion date
- Jan 2027
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- NCT number
- NCT02671448
What you commit to
- Study type: Interventional
- Participants enrolled: 83
- From Jan 2016 to the primary completion date, Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with a documented active infection prior to starting their preparative regimen. This includes grade 3 or higher viral, bacterial, or fungal infection.
- Inability of patient or caregiver to speak or read English (we currently do not have the manpower to translate nor staff a multilingual homebound stem cell transplant program with adequate educational materials).
Other illness
- Uncontrolled arrhythmias
- Active or uncontrolled pulmonary disease
- Sorror Co-morbidity index ≥ 4 except in patients with history of resected cancers
Lab values
- Creatinine clearance (calculated or measured) of \< 50 cc/minute
Other
- Karnofsky Performance Scale (KPS) score \<80
- Inadequate housing arrangements
- Inadequate caregiver arrangements
Who the study is looking for
- Diagnosis of Plasma cell dyscrasia
- Treatment plan including Autologous HSCT
- 18-80 years of age
- Appropriate homebound setting as defined by one of the following:
- Lodging at the MSK Residence.
- Staying at home or a "home equivalent" in any one of the zip codes as outlined in the appendix. Home equivalent is defined as a residence which may or may not be the primary residence of the patient.
- "Home equivalent" must pass the "Home Environment Screening Tool" for homebound stem cell transplantation (not required for other MSK recognized lodging facility).
- Adequate caregiver support as defined by:
- Single or multiple informal caregivers willing and able to provide 24 hour a day, seven day a week supervision of the transplant recipient in their home or "home-like" environment.
- Caregiver willing and able to fulfill the basic stem cell transplant caregiver education requirements as determined by caregiver and healthcare team, including social worker
- Have Wi-Fi connection
- Appropriate third party payer coverage for "Homebound Stem Cell Transplant Program"
- Both patient and caregiver willing to give and sign informed consent.
Age in the registry: 18 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.